Insider Sale by CFO

On July 1, 2026, Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics Inc. (NASDAQ:SYRE), sold a total of 7,500 shares of the company’s common stock for $658,039. The transactions were executed under a Rule 10b5‑1 trading plan that the company adopted on November 10, 2025.

The sale comprised two separate blocks: 5,775 shares were sold at a weighted‑average price of $87.55 per share, with individual transaction prices ranging from $87.13 to $88.05; an additional 1,725 shares were sold at a weighted‑average price of $88.37 per share, with prices ranging from $88.17 to $89.01.

Option Exercise and Holdings

Prior to the sales, Burrows exercised stock options to acquire the same 7,500 shares at an exercise price of $14.50 per share, resulting in a cash outlay of $108,750. These options were part of a larger grant of 404,857 shares that follows a vesting schedule. After completing the sales, Burrows directly holds 97,994 shares of Spyre common stock. This total includes 67,476 restricted stock units (RSUs) that will vest in two equal installments on September 1, 2026, and September 1, 2027, provided he remains employed with the company.

Clinical Trial Updates

In parallel news, Spyre reported positive outcomes from its phase 2 SKYLINE trial of the experimental drug SPY002 for moderately‑to‑severely active ulcerative colitis, showing a statistically significant reduction in the Robart’s Histopathology Index score. The company also announced completion of enrollment for its SKYWAY basket trial, which is evaluating SPY072 across various rheumatic diseases, with results expected in 2026.

Analyst Reactions

Following the trial data and insider activity, Deutsche Bank raised its price target for Spyre to $115 while maintaining a Buy rating, and Stifel increased its target to $107, also maintaining a Buy rating. Both firms cited the strong clinical data as the basis for the upward revisions.

Other Insider Activity

The article also noted a separate significant insider transaction: Fairmount Healthcare Fund II L.P. sold over 4.6 million shares of Spyre, valued at approximately $399.7 million.